Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain

Vicente Estrada(Instituto de Salud Carlos III), Arturo Fernández Cruz(Hospital Clínico San Carlos), Celia Miralles, Alejandra Ortega(Hospital Clínico San Carlos), Marı́a Jesús Pérez-Elı́as(Hospital Universitario Ramón y Cajal), Julián Olalla(Hospital Costa del Sol), Peré Domingo(Hospital de Sant Pau), Fernando Lozano(Hospital Universitario de Valme), Mar Masiá(Universidad de Alcalá), Jesús Santos(Hospital Clínico Universitario Virgen de la Victoria), José Antonio Iribarren(Biogipuzkoa Health Research Institute), José Ignacio Bernardino(Hospital Universitario La Paz)
HIV Clinical Trials
January 22, 2015
10.1179/1528433614z.0000000008
Cited by 21

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort
|The Lancet HIV|2020|396
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
|The Lancet|2006|343